Healios K.K.
HLOSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.30 | 0.96 | 7.25 | 1.39 |
| FCF Yield | -11.30% | -2.04% | -4.47% | -6.12% |
| EV / EBITDA | -8.17 | -50.88 | -22.77 | -16.59 |
| Quality | ||||
| ROIC | -27.01% | -25.26% | -34.98% | -26.01% |
| Gross Margin | 77.14% | 89.26% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.45 | 0.74 | 0.86 | 1.14 |
| Growth | ||||
| Revenue 3-Year CAGR | 83.93% | 43.44% | 49.38% | -22.77% |
| Free Cash Flow Growth | 25.47% | 41.39% | 9.76% | -26.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.46 | 0.81 | 0.02 | 0.62 |
| Interest Coverage | -1.79 | -4.80 | -10.36 | -6.71 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,303.00 | -5,452.26 | 1,184.22 | 3,560.98 |